Clinical trial NCT05610826: Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
Official title: Preoperative PRRT Versus Surgical Cytoreduction Alone in Metastatic Pancreatic Neuroendocrine Tumors to the Liver: A Phase II Multi-institutional Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Pancreatic Neuroendocrine Tumor
Pancreas Cancer
Keywords: pancreatic cancer
pancreas cancer
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2022-11-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Doctors and researchers leading this study hope to learn more about peptide receptor radionuclide therapy (PRRT) in combination with cytoreduction (surgically removing tumors). They hope to learn if combining PRRT in combination with cytoreduction would be more effective than cytoreduction alone. PRRT itself is approved by the U.S. Food and Drug Administration (FDA) for people with PanNETs however the combination with cytoreduction is considered experimental.

Your participation in this research will last about 2 years. The purpose of this research is to gather information on the safety and effectiveness of PRRT.

Detailed description: Doctors and researchers leading this study hope to learn more about peptide receptor radionuclide therapy (PRRT) in combination with cytoreduction (surgically removing tumors). They hope to learn if combining PRRT in combination with cytoreduction would be more effective than cytoreduction alone. PRRT itself is approved by the U.S. Food and Drug Administration (FDA) for people with PanNETs however the combination with cytoreduction is considered experimental.

Your participation in this research will last about 2 years. The purpose of this research is to gather information on the safety and effectiveness of PRRT.

PRRT is a form of targeted treatment (think of a "lock and key") done by the use of a small molecule (Lutathera) Lutathera acts as a "key" to "lock" onto certain areas your tumor cells called receptors when injected into a vein and travels through the bloodstream. Lutetium-177 is the radionuclide in Lutathera which is a chemical that delivers strong radiation directly into your tumor cells and works by causing death of the cancerous tissues.

PRRT can only be done on patients who have tumors that have the somatostatin receptors. Before being given PRRT, your treating doctor will run imaging tests to make sure your tumors have these targeted receptors. Your participation in this research will last about 2 years. The purpose of this research is to gather information on the safety and effectiveness of PRRT.

Participants will be randomized (like the flip of a coin) to one of two arms. Arm 1 is the control arm, which will undergo standard of care cytoreductive surgery (for the tumor). Arm 2 will undergo four cycles of PRRT before cytoreductive surgery.

Eligibility criteria: Inclusion Criteria:

* Metastatic Pancreatic neuroendocrine tumors (PanNET) to the liver
* Well- or moderately differentiated (grade 1 or grade 2, Ki-
* Ability to aim for equal or greater than 90% hepatic cytoreduction surgically
* Proof of SSTR2 expression by uptake of tumor on 68Ga DOTATATE PET CT (Krenning Score on all or a majority of lesions
* Age older than 18 years
* No Somatostatin Analogues (SSA) or other systemic therapy for 4 weeks prior to starting PRRT, if randomized to arm 2.

Exclusion Criteria:

* Patient with G3 or poorly differentiated NET (grade 3, Ki-67 \>20%)
* Previous liver-directed therapy with Yttrium-90 (TACE/TAE allowed if performed more than 12 months prior to enrollment)
* Systemic therapy with Capecitabine and/or Temozolamide within 12 months of enrollment.
* No tumor uptake on 68Ga DOTATATE PET CT
* Liver tumor burden \> 50% (as defined by CT or MRI)
* Signs of early liver failure (T-Bilirubin \>3, INR \> 1.5, Albumin \<3.0 g/dL unless prothrombin time is within the normal range) or cirrhosis or ascites
* calculated by the Cockroft Gault method, eventually confirmed by measured creatinine clearance
* (or measured glomerular filtration rate (GFR) using plasma clearance methods, not gamma
* camera-based) \<50 mL/min (the measured creatinine clearance / GFR is required only as - confirmatory exam).
* 2. Hb concentration \<5.0 mmol/L (\<8.0 g/dL); WBC \<2x109/L (2000/mm3); platelets \<75x109/L - (75x103/mm3).
* Known brain metastases, unless these metastases have been treated and stabilized.
* Uncontrolled congestive heart failure (NYHA II, III, IV).
* Uncontrolled diabetes mellitus as defined by a fasting blood glucose \>2 ULN.
* Pregnancy or lactation.
* For female patients of childbearing potential (defined as \< 2 years after last menstruation and not surgically sterile) and male patients, who are not surgically sterile or with female partners of childbearing potential: absence of effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel). - Prior external beam radiation therapy to more than 25% of the bone marrow.
* Current spontaneous urinary incontinence making impossible the safe administration of the radioactive IMP.
* Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence.
* Patients who have not provided a signed informed consent form to accept this treatment.
* Poor renal function
* Quality Unit language added
* editorial changes

Primary outcomes:
measure: Progression-free Survival
timeFrame: 2 years
Secondary outcomes:
measure: Overall Survival
timeFrame: 2 years
measure: Objective Response Rate
timeFrame: 2 Years
measure: Increase in Progression Free Survival
timeFrame: 2 years
measure: Improvement in Progression-Free Survival (PFS2)
timeFrame: 2 years
measure: Improvement in Overall Survival
timeFrame: 2 years
measure: Difference in imaging characteristics
timeFrame: 2 years
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago Comprehensive Cancer Center
state: Illinois
Study officials:
affiliation: University of Chicago
name: Xavier Keutgen, MD
role: PRINCIPAL_INVESTIGATOR
References: